Cargando…

Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing

Prostate cancer is the second most frequent malignancy in men worldwide. Despite the improvement in survival achieved by increasingly early diagnosis and advances in treatment, it is still associated with high mortality. Because of its molecular heterogeneity, there is a need to identify genetic alt...

Descripción completa

Detalles Bibliográficos
Autores principales: Nogueira Costa, Inês, Reis, Joana, Meireles, Sara, Ribeiro, Maria João, Barbosa, Miguel, Augusto, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SMC Media Srl 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239024/
https://www.ncbi.nlm.nih.gov/pubmed/35774732
http://dx.doi.org/10.12890/2022_003331
_version_ 1784737192596209664
author Nogueira Costa, Inês
Reis, Joana
Meireles, Sara
Ribeiro, Maria João
Barbosa, Miguel
Augusto, Isabel
author_facet Nogueira Costa, Inês
Reis, Joana
Meireles, Sara
Ribeiro, Maria João
Barbosa, Miguel
Augusto, Isabel
author_sort Nogueira Costa, Inês
collection PubMed
description Prostate cancer is the second most frequent malignancy in men worldwide. Despite the improvement in survival achieved by increasingly early diagnosis and advances in treatment, it is still associated with high mortality. Because of its molecular heterogeneity, there is a need to identify genetic alterations in order to apply targeted therapies. Increasing evidence suggests that the PARP inhibitor olaparib could have a significant synthetic lethal effect in prostate cancer with homologous recombination defects, such as BRCA1/2 mutations. It is not yet known if, under these circumstances, platinum-based chemotherapy induces higher response rates in prostate cancer. We present the case of a patient with BRCA2-mutated metastatic castration-resistant prostate cancer whose treatment sequence included carboplatin and olaparib. LEARNING POINTS: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease despite significant progress in treatment. The BRCA2 mutation is associated with worse survival and so timely genetic screening is important. Studies are needed to identify the best therapeutic sequencing strategy for mCRPC harbouring homologous recombination repair defects, which includes PARP inhibitors and platinum.
format Online
Article
Text
id pubmed-9239024
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SMC Media Srl
record_format MEDLINE/PubMed
spelling pubmed-92390242022-06-29 Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing Nogueira Costa, Inês Reis, Joana Meireles, Sara Ribeiro, Maria João Barbosa, Miguel Augusto, Isabel Eur J Case Rep Intern Med Articles Prostate cancer is the second most frequent malignancy in men worldwide. Despite the improvement in survival achieved by increasingly early diagnosis and advances in treatment, it is still associated with high mortality. Because of its molecular heterogeneity, there is a need to identify genetic alterations in order to apply targeted therapies. Increasing evidence suggests that the PARP inhibitor olaparib could have a significant synthetic lethal effect in prostate cancer with homologous recombination defects, such as BRCA1/2 mutations. It is not yet known if, under these circumstances, platinum-based chemotherapy induces higher response rates in prostate cancer. We present the case of a patient with BRCA2-mutated metastatic castration-resistant prostate cancer whose treatment sequence included carboplatin and olaparib. LEARNING POINTS: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease despite significant progress in treatment. The BRCA2 mutation is associated with worse survival and so timely genetic screening is important. Studies are needed to identify the best therapeutic sequencing strategy for mCRPC harbouring homologous recombination repair defects, which includes PARP inhibitors and platinum. SMC Media Srl 2022-05-24 /pmc/articles/PMC9239024/ /pubmed/35774732 http://dx.doi.org/10.12890/2022_003331 Text en © EFIM 2022 This article is licensed under a Commons Attribution Non-Commercial 4.0 License
spellingShingle Articles
Nogueira Costa, Inês
Reis, Joana
Meireles, Sara
Ribeiro, Maria João
Barbosa, Miguel
Augusto, Isabel
Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
title Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
title_full Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
title_fullStr Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
title_full_unstemmed Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
title_short Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
title_sort metastatic castration-resistant prostate cancer with brca2 mutation: the challenge incorporating parp inhibitors and platinum in treatment sequencing
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239024/
https://www.ncbi.nlm.nih.gov/pubmed/35774732
http://dx.doi.org/10.12890/2022_003331
work_keys_str_mv AT nogueiracostaines metastaticcastrationresistantprostatecancerwithbrca2mutationthechallengeincorporatingparpinhibitorsandplatinumintreatmentsequencing
AT reisjoana metastaticcastrationresistantprostatecancerwithbrca2mutationthechallengeincorporatingparpinhibitorsandplatinumintreatmentsequencing
AT meirelessara metastaticcastrationresistantprostatecancerwithbrca2mutationthechallengeincorporatingparpinhibitorsandplatinumintreatmentsequencing
AT ribeiromariajoao metastaticcastrationresistantprostatecancerwithbrca2mutationthechallengeincorporatingparpinhibitorsandplatinumintreatmentsequencing
AT barbosamiguel metastaticcastrationresistantprostatecancerwithbrca2mutationthechallengeincorporatingparpinhibitorsandplatinumintreatmentsequencing
AT augustoisabel metastaticcastrationresistantprostatecancerwithbrca2mutationthechallengeincorporatingparpinhibitorsandplatinumintreatmentsequencing